JH-RE-06 |
Catalog No.GC36367 |
강력한 REV1-REV7 계면 억제제인 JH-RE-06(IC50=0.78μM, Kd=0.42μM)은 POLζ의 REV7 소단위와 상호작용하는 REV1을 표적으로 한다. JH-RE-06은 돌연변이 유발성 POLζ의 모집을 방지하여 돌연변이 유발성 전이 합성(TLS)을 방해합니다. JH-RE-06은 화학 요법을 개선합니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1361227-90-8
Sample solution is provided at 25 µL, 10mM.
JH-RE-06, a potent REV1-REV7 interface inhibitor (IC50=0.78 μM; Kd=0.42 μM), targets REV1 that interacts with the REV7 subunit of POLζ. JH-RE-06 disrupts mutagenic translesion synthesis (TLS) by preventing recruitment of mutagenic POLζ. JH-RE-06 enhances Cisplatin-induced cytotoxicity and improves chemotherapy[1][2]. IC50: 0.78 μM (REV1-REV7)[1]Kd: 0.42 μM (REV1-REV7)[1]
JH-RE-06 unexpectedly induces dimerization of the REV1 CTD at its REV7-binding surface and blocks the REV1-REV7 interaction[1].
JH-RE-06 inhibits mutagenic TLS and enhances cisplatin-induced toxicity in cultured human and mouse cell lines[1]. Co-administration of JH-RE-06 with cisplatin suppresses the growth of xenograft human melanomas in mice[1].
[1]. Wojtaszek JL, et al. A Small Molecule Targeting Mutagenic Translesion Synthesis Improves Chemotherapy. Cell. 2019 Jun 27;178(1):152-159.e11. [2]. REV1-POLς Inhibition Enhances Cisplatin-Induced Cytotoxicity. Cancer Discov. 2019 Aug;9(8):OF17.
Average Rating: 5
(Based on Reviews and 17 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *